Skip to main content
PMC home page
The BMJ logoLink to The BMJ
. 1991 Aug 24;303(6800):435–437. doi: 10.1136/bmj.303.6800.435

Fatal myocardial infarction in the Scottish adjuvant tamoxifen trial. The Scottish Breast Cancer Committee.

C C McDonald 1, H J Stewart 1
PMCID: PMC1670561  PMID: 1912833

Abstract

OBJECTIVE--To investigate the incidence of fatal myocardial infarction in women in the two randomised arms of the Scottish adjuvant tamoxifen trial. DESIGN--Retrospective review of hospital notes to determine with the greatest possible certainty women who had died of an acute myocardial infarction. SETTING--Scottish Cancer Trials Office, the University of Edinburgh. PATIENTS--1070 postmenopausal women with operable breast cancer who were randomised to receive either adjuvant tamoxifen for five years or until relapse (539 patients) or tamoxifen for at least six weeks on the confirmation of first recurrence (531 patients). MAIN OUTCOME MEASURES--Incidence of fatal myocardial infarction in women with no known or suspected systemic cancer. RESULTS--Of the 200 women who died in the adjuvant tamoxifen arm of the trial, 44 were free of cancer at death and 10 of these died of myocardial infarction. In the observation arm 251 women died, of whom 61 showed no evidence of systemic cancer and 25 had a fatal myocardial infarction. The incidence of fatal myocardial infarction in the two groups was significantly different (chi 2 = 6.88, p = 0.0087). CONCLUSION--Tamoxifen given for at least five years as adjuvant therapy for breast cancer seems to have a cardioprotective oestrogen-like effect in postmenopausal women.

Full text

PDF
436

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bertelli G., Pronzato P., Amoroso D., Cusimano M. P., Conte P. F., Montagna G., Bertolini S., Rosso R. Adjuvant tamoxifen in primary breast cancer: influence on plasma lipids and antithrombin III levels. Breast Cancer Res Treat. 1988 Dec;12(3):307–310. doi: 10.1007/BF01811244. [DOI] [PubMed] [Google Scholar]
  2. Bourne T., Hillard T. C., Whitehead M. I., Crook D., Campbell S. Oestrogens, arterial status, and postmenopausal women. Lancet. 1990 Jun 16;335(8703):1470–1471. doi: 10.1016/0140-6736(90)91505-5. [DOI] [PubMed] [Google Scholar]
  3. Bruning P. F., Bonfrer J. M., Hart A. A., de Jong-Bakker M., Linders D., van Loon J., Nooyen W. J. Tamoxifen, serum lipoproteins and cardiovascular risk. Br J Cancer. 1988 Oct;58(4):497–499. doi: 10.1038/bjc.1988.248. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Caleffi M., Fentiman I. S., Clark G. M., Wang D. Y., Needham J., Clark K., La Ville A., Lewis B. Effect of tamoxifen on oestrogen binding, lipid and lipoprotein concentrations and blood clotting parameters in premenopausal women with breast pain. J Endocrinol. 1988 Nov;119(2):335–339. doi: 10.1677/joe.0.1190335. [DOI] [PubMed] [Google Scholar]
  5. Cole M. P., Jones C. T., Todd I. D. A new anti-oestrogenic agent in late breast cancer. An early clinical appraisal of ICI46474. Br J Cancer. 1971 Jun;25(2):270–275. doi: 10.1038/bjc.1971.33. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Dahan R., Espie M., Mignot L., Houlbert D., Chanu B. Tamoxifen and arterial thrombosis. Lancet. 1985 Mar 16;1(8429):638–638. doi: 10.1016/s0140-6736(85)92173-7. [DOI] [PubMed] [Google Scholar]
  7. Fisher B., Brown A., Wolmark N., Redmond C., Wickerham D. L., Wittliff J., Dimitrov N., Legault-Poisson S., Schipper H., Prager D. Prolonging tamoxifen therapy for primary breast cancer. Findings from the National Surgical Adjuvant Breast and Bowel Project clinical trial. Ann Intern Med. 1987 May;106(5):649–654. doi: 10.7326/0003-4819-106-5-649. [DOI] [PubMed] [Google Scholar]
  8. Furr B. J., Jordan V. C. The pharmacology and clinical uses of tamoxifen. Pharmacol Ther. 1984;25(2):127–205. doi: 10.1016/0163-7258(84)90043-3. [DOI] [PubMed] [Google Scholar]
  9. Henderson B. E., Paganini-Hill A., Ross R. K. Estrogen replacement therapy and protection from acute myocardial infarction. Am J Obstet Gynecol. 1988 Aug;159(2):312–317. doi: 10.1016/s0002-9378(88)80074-7. [DOI] [PubMed] [Google Scholar]
  10. Love R. R., Mazess R. B., Tormey D. C., Barden H. S., Newcomb P. A., Jordan V. C. Bone mineral density in women with breast cancer treated with adjuvant tamoxifen for at least two years. Breast Cancer Res Treat. 1988 Dec;12(3):297–302. doi: 10.1007/BF01811242. [DOI] [PubMed] [Google Scholar]
  11. Love R. R., Newcomb P. A., Wiebe D. A., Surawicz T. S., Jordan V. C., Carbone P. P., DeMets D. L. Effects of tamoxifen therapy on lipid and lipoprotein levels in postmenopausal patients with node-negative breast cancer. J Natl Cancer Inst. 1990 Aug 15;82(16):1327–1332. doi: 10.1093/jnci/82.16.1327. [DOI] [PubMed] [Google Scholar]
  12. Osborne C. K., Hobbs K., Clark G. M. Effect of estrogens and antiestrogens on growth of human breast cancer cells in athymic nude mice. Cancer Res. 1985 Feb;45(2):584–590. [PubMed] [Google Scholar]
  13. Powles T. J., Hardy J. R., Ashley S. E., Farrington G. M., Cosgrove D., Davey J. B., Dowsett M., McKinna J. A., Nash A. G., Sinnett H. D. A pilot trial to evaluate the acute toxicity and feasibility of tamoxifen for prevention of breast cancer. Br J Cancer. 1989 Jul;60(1):126–131. doi: 10.1038/bjc.1989.235. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Turken S., Siris E., Seldin D., Flaster E., Hyman G., Lindsay R. Effects of tamoxifen on spinal bone density in women with breast cancer. J Natl Cancer Inst. 1989 Jul 19;81(14):1086–1088. doi: 10.1093/jnci/81.14.1086. [DOI] [PubMed] [Google Scholar]
  15. Turner R. T., Wakley G. K., Hannon K. S., Bell N. H. Tamoxifen inhibits osteoclast-mediated resorption of trabecular bone in ovarian hormone-deficient rats. Endocrinology. 1988 Mar;122(3):1146–1150. doi: 10.1210/endo-122-3-1146. [DOI] [PubMed] [Google Scholar]

Articles from BMJ : British Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES